Results 41 to 50 of about 6,619 (182)

Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

open access: yesBMC Nephrology, 2017
Background Tolvaptan slows progression of autosomal dominant polycystic kidney disease (ADPKD) by antagonizing the vasopressin-cAMP axis. Nitric oxide (NO) stimulates natriuresis and diuresis, but its role is unknown during tolvaptan treatment in ADPKD ...
Safa Al Therwani   +4 more
doaj   +1 more source

Comparison of the change in annual growth rate of total kidney volume between the tolvaptan group and the non-tolvaptan group.

open access: yes, 2022
The median difference in the annual change in TKV was not statistically different between the tolvaptan group (0.2 (range -30.3, 22.5)) and the non-tolvaptan group (2.0 (-15.6, 16.6)) (p = 0.39, Wilcoxon rank sum test).
Akinari Sekine (4357189)   +8 more
core   +1 more source

Comparison of the change in annual growth rate of total liver volume between the tolvaptan group and the non-tolvaptan group.

open access: yes, 2022
The median difference in the annual change in TLV was not statistically different between the tolvaptan group (-0.8 (-15.9, 16.7) %/year) and the non-tolvaptan group (1.7 (-15.6, 18.7)) (p = 0.52, Wilcoxon rank sum test). TLV; total liver volume, ΔTLV %;
Akinari Sekine (4357189)   +8 more
core   +1 more source

Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan

open access: yesTherapeutic Advances in Cardiovascular Disease, 2019
Background: Although tolvaptan, an electrolyte-free water diuretic for congestive heart failure (HF), is reported to have no effect on long-term mortality or HF-related morbidity, there may exist some subgroups of patients who may receive beneficial ...
Kensuke Fujioka   +10 more
doaj   +1 more source

Tolvaptan Attenuates Left Ventricular Fibrosis After Acute Myocardial Infarction in Rats

open access: yesJournal of Pharmacological Sciences, 2013
Tolvaptan, a non-peptide V2-receptor antagonist, is a newly developed diuretic agent. Recently, we reported that tolvaptan has diuretic as well as anti-inflammatory and anti-fibrotic actions in chronic heart failure.
Takanori Yamazaki   +10 more
doaj   +1 more source

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease [PDF]

open access: yes, 2019
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).

core   +4 more sources

Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort

open access: yesScientific Reports, 2023
Tolvaptan is the first disease-modifying drug proven to slow eGFR decline in high-risk patients with ADPKD. However, barriers from the patient perspective to its use in real-life settings have not been systemically examined in a large cohort.
Luca Calvaruso   +8 more
doaj   +1 more source

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

open access: yesBMC Nephrology, 2019
Background The short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represents a validated approach to ...
Hayley Bennett   +3 more
doaj   +1 more source

Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan

open access: yesKidney Medicine, 2020
Rationale & Objective: Euvolemic hyponatremia often occurs due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vasopressin 2 receptor antagonists may be used to treat SIADH.
Ramy M. Hanna   +10 more
doaj   +1 more source

Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study

open access: yesAnnals of Hepatology, 2017
Introduction and aim: Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free water excretion, but its efficacy and safety in cirrhotic
Ji-Dong Jia   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy